Filtered By:
Specialty: Neurology

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 782 results found since Jan 2013.

The European Narcolepsy Network (EU ‐NN) database
Summary Narcolepsy with cataplexy is a rare disease with an estimated prevalence of 0.02% in European populations. Narcolepsy shares many features of rare disorders, in particular the lack of awareness of the disease with serious consequences for healthcare supply. Similar to other rare diseases, only a few European countries have registered narcolepsy cases in databases of the International Classification of Diseases or in registries of the European health authorities. A promising approach to identify disease‐specific adverse health effects and needs in healthcare delivery in the field of rare diseases is to establish a...
Source: Journal of Sleep Research - January 25, 2016 Category: Neurology Authors: Ramin Khatami, Gianina Luca, Christian R. Baumann, Claudio L. Bassetti, Oliviero Bruni, Francesca Canellas, Yves Dauvilliers, Rafael Del Rio ‐Villegas, Eva Feketeova, Raffaele Ferri, Peter Geisler, Birgit Högl, Poul Jennum, Birgitte R. Kornum, Michel L Tags: Narcolepsy database Source Type: research

Narcolepsy and influenza A(H1N1) pandemic 2009 vaccination in the United States
Conclusions: Influenza vaccines containing the A(H1N1)pdm09 virus strain used in the United States were not associated with an increased risk of narcolepsy. Vaccination with the influenza A(H1N1)pdm09 vaccine viral antigens does not appear to be sufficient by itself to increase the incidence of narcolepsy in a population.
Source: Neurology - November 10, 2014 Category: Neurology Authors: Duffy, J., Weintraub, E., Vellozzi, C., DeStefano, F., On behalf of the Vaccine Safety Datalink Tags: Narcolepsy, Cohort studies, Incidence studies ARTICLE Source Type: research

Measurement of narcolepsy symptoms: The Narcolepsy Severity Scale
Conclusions: The NSS can be considered a reliable and valid clinical tool for the quantification of narcolepsy symptoms to monitor and optimize narcolepsy management.
Source: Neurology - April 3, 2017 Category: Neurology Authors: Dauvilliers, Y., Beziat, S., Pesenti, C., Lopez, R., Barateau, L., Carlander, B., Luca, G., Tafti, M., Morin, C. M., Billiard, M., Jaussent, I. Tags: Narcolepsy ARTICLE Source Type: research

Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination
Conclusion: Pandemrix vaccination is a precipitating factor for narcolepsy, especially in combination with HLA-DQB1*0602. The incidence of narcolepsy was 25 times higher after the vaccination compared with the time period before. The children in the postvaccination group had a lower age at onset and a more sudden onset than that generally seen.
Source: Neurology - April 1, 2013 Category: Neurology Authors: Szakacs, A., Darin, N., Hallbook, T. Tags: All Pediatric, Narcolepsy, Risk factors in epidemiology ARTICLE Source Type: research

Key sleep neurologic disorders: Narcolepsy, restless legs syndrome/Willis-Ekbom disease, and REM sleep behavior disorder
Sleep disorders are frequent comorbidities in neurologic patients. This review focuses on clinical aspects and prognosis of 3 neurologic sleep disorders: narcolepsy, restless legs syndrome/Willis-Ekbom disease (RLS/WED), and REM sleep behavior disorder (RBD). Narcolepsy causes pervasive, enduring excessive daytime sleepiness, adversely affecting patients' daily functioning. RLS/WED is characterized by an uncomfortable urge to move the legs before sleep, often evolving toward augmentation and resulting in daylong bothersome symptoms. RBD causes potentially injurious dream enactment behaviors that often signify future evolut...
Source: Nature Clinical Practice - February 17, 2014 Category: Neurology Authors: St. Louis, E. K. Tags: Prognosis, Narcolepsy, Parasomnias, Restless legs syndrome Clinical and Ethical Challenges Source Type: research

Complete loss of F-waves during cataplectic attacks in patients with narcolepsy
We present F-wave recordings in 3 patients with N1 before, during, and after a CA (figure) to test whether the level of spinal excitability in cataplexy equals that in REM sleep.
Source: Neurology - November 24, 2014 Category: Neurology Authors: Salih, F., Grosse, P. Tags: Narcolepsy, All clinical neurophysiology CLINICAL/SCIENTIFIC NOTES Source Type: research

Efficacy of sodium oxybate on REM sleep behavior disorder in a patient with narcolepsy type 1
Idiopathic REM sleep behavior disorder (iRBD) is a rare disease (0.0038%–0.005%).1 In patients with narcolepsy type 1 (NT1), symptomatic RBD is a frequent, comorbid disease, ranging from 45% to 61%.2 iRBD is a premotor stage of neurodegenerative disease. Few patients with narcolepsy develop Alzheimer disease or Parkinson disease.3 Treatment studies in patients with RBD are rare and have small sample sizes and heterogeneous populations and methods.4 Sodium oxybate (SO) has been efficacious in 2 patients with iRBD.5,6
Source: Neurology - December 11, 2016 Category: Neurology Authors: Mayer, G. Tags: Narcolepsy, Parasomnias CLINICAL/SCIENTIFIC NOTES Source Type: research

Primary progressive narcolepsy type 1: The other side of the coin
Narcolepsy type 1 (NT1) is characterized by hypersomnolence associated with early occurrence of REM sleep (i.e., sleep-onset REM periods [SOREMP]) and cataplexy (i.e., sudden loss of muscle tone evoked by emotions), or with CSF hypocretin-1 (CSF hcrt-1) low levels (below 110 pg/mL, undetectable in most cases). Compelling evidence indicates that NT1 is caused by an autoimmune disease affecting HLA-DQB1*06:02 carriers.1 Diagnostic workup requires a history of cataplexy and multiple SOREMP at sleep studies (nocturnal polysomnography and multiple sleep latency test [MSLT]) or CSF hcrt-1 deficiency.2 At diagnosis, most patients...
Source: Neurology - December 1, 2014 Category: Neurology Authors: Pizza, F., Vandi, S., Liguori, R., Parchi, P., Avoni, P., Mignot, E., Plazzi, G. Tags: Narcolepsy, Other hypersomnias CLINICAL/SCIENTIFIC NOTES Source Type: research

Monozygotic twins discordant for narcolepsy type 1 and multiple sclerosis
Narcolepsy type 1 (NC1) is a neurologic sleep disorder caused by the loss of hypothalamic neurons that produce the sleep–wake regulating neuropeptides, the hypocretins (orexins). The pathogenesis is believed to be mainly autoimmune, based on the observation of a 95% to 100% association with the HLA-DQB1*06:02 allele, and on the recent strong indication of antigen presentation to T cells as central factors.1 In Caucasians and Asians, the DQB1*06:02 allele is tightly linked to the HLA-DRB1*15:01 allele, which itself is associated with multiple sclerosis (MS), a CNS autoimmune disorder. Herein, we describe a DRB1*15:01/...
Source: Neurology Neuroimmunology and Neuroinflammation - June 15, 2016 Category: Neurology Authors: Jennum, P. J., Kornum, B. R., Issa, N. M., Gammeltoft, S., Tommerup, N., Morling, N., Tümer, Z., Knudsen, S. Tags: Autoimmune diseases, Narcolepsy, Class IV, Multiple sclerosis Clinical/Scientific Notes Source Type: research

Long-term improvement after combined immunomodulation in early post-H1N1 vaccination narcolepsy
We report here an early post-H1N1 vaccination NT1 case treated with combined immunomodulation of IVIg and methylprednisolone, and a comparable sporadic NT1 case.
Source: Neurology Neuroimmunology and Neuroinflammation - August 7, 2017 Category: Neurology Authors: Viste, R., Soosai, J., Vikin, T., Thorsby, P. M., Nilsen, K. B., Knudsen, S. Tags: Autoimmune diseases, Narcolepsy Clinical/Scientific Notes Source Type: research

CSF orexin-A levels after rituximab treatment in recent onset narcolepsy type 1
A 28-year-old man with narcolepsy type 1 (NT1) was referred due to excessive daytime sleepiness starting 5 months earlier, and 2 months prior to his admission, he had 1 to 3 daily cataplexies related to laughter, anger, and surprise, leading to a loss of muscle tone in the face, neck, and legs. Inquiries with Epworth Sleepiness Scale (ESS) was initially 21 of 24 points. Prior to admission, his medical history was insignificant, and physical examination did not show any neurologic deficits.
Source: Neurology Neuroimmunology and Neuroinflammation - September 3, 2019 Category: Neurology Authors: Wasling, P., Malmeström, C., Blennow, K. Tags: Autoimmune diseases, Narcolepsy Clinical/Scientific Notes Source Type: research

Gut microbiota composition is associated with narcolepsy type 1
Conclusion We provide evidence of gut microbial community structure alterations in NT1. However, further larger and longitudinal multiomics studies are required to replicate and elucidate the relationship between the gut microbiota, immunity dysregulation and NT1.
Source: Neurology Neuroimmunology and Neuroinflammation - October 9, 2020 Category: Neurology Authors: Lecomte, A., Barateau, L., Pereira, P., Paulin, L., Auvinen, P., Scheperjans, F., Dauvilliers, Y. Tags: Narcolepsy Article Source Type: research

Post-H1N1 Flu Vaccination Narcolepsy in Switzerland: A Retrospective Survey in the 30 Sleep-Certified Swiss Centers
Narcolepsy-cataplexy is a sleep-wake disorder and suggested to be immune-mediated, involving genetic and environmental factors. The autoimmune process eventually leads to a loss of hypocretin neurons in the lateral hypothalamus. Epidemiological studies in several countries proved an increased incidence of narcolepsy after H1N1 flu vaccination and infection. This survey in 30 sleep centers in Switzerland led to the identification of 9 H1N1-vaccinated children and adults as newly diagnosed narcolepsy. Clinical features included the abrupt and severe onset of sleepiness, cataplexy and sleep fragmentation.Eur Neurol 2016;75:105-108
Source: European Neurology - February 22, 2016 Category: Neurology Source Type: research

Association between H1N1 vaccination and narcolepsy-cataplexy: Flu to sleep
After the beginning of the influenza A (H1N1 pdm09) pandemic in 2009, several monovalent pandemic H1N1 vaccines were licensed using fast track procedures, with limited safety data in children and adolescents.1 Nonadjuvant monovalent vaccines were used in the United States and Australia, and on a limited scale, in Europe (France, Spain) and other countries. Within the European Union (EU), 2 different vaccines with adjuvant were licensed, both containing a new generation of squalene-based adjuvant: Focetria (Novartis, Philadelphia, PA), with the MF59 adjuvant, and Pandemrix (GSK, Philadelphia, PA), containing AS03 (squalene ...
Source: Neurology - April 1, 2013 Category: Neurology Authors: Kothare, S. V., Wiznitzer, M. Tags: All Pediatric, Narcolepsy, Risk factors in epidemiology EDITORIALS Source Type: research

The prevalence of narcolepsy in Catalunya (Spain)
Summary Previous studies have estimated an overall prevalence for narcolepsy between 15 and 70 cases per 100 000 inhabitants. We aimed to estimate the prevalence of narcolepsy in Catalunya (Catalonia), a north‐east region of Spain (7 424 754 inhabitants), on 31 December 2014 by identifying all living subjects diagnosed with narcolepsy. First, we identified patients diagnosed by one of the 13 sleep, paediatric or neurological departments that perform tests regularly to diagnose narcolepsy. In a second phase, we searched for additional patients with narcolepsy in a clinical database of the primary health‐care system. ...
Source: Journal of Sleep Research - November 24, 2017 Category: Neurology Authors: Ester TI Ó, Carles Gaig, Maria Giner‐Soriano, Odile Romero, Maria‐José Jurado, Gemma Sansa, Montse Pujol, Oscar Sans, Ion Álvarez‐Guerrico, Nuria Caballol, Marta Jimenez, Juan‐Luis Becerra, Antonio Escartin, Carmen Monasterio, Albert Molins, An Tags: Regular Research Paper Source Type: research